Frontlight ResearchEarly access
TerminatedPhase 2
Ketamine for OUD and Suicidal Ideation in the ED
Key facts
- Who runs it
- Brigham and Women's Hospital
- Where
- Boston, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 4 people enrolled
- Started
- 14 Jun 2024
- Ended
- 31 Mar 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Ketamine
- Saline Solution
- Record updated
- 8 April 2025
- Why it stopped
- Low recruitment numbers and study funding will be closing shortly.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Other criteria
- Inclusion/Exclusion Criteria:
- To be eligible, individuals must be/have:
- English speaking adults aged 18 and above
- Diagnosed with DSM5 opioid use disorder, moderate or severe, or clinically suspected opioid use disorder
- Endorsing suicidal ideation sufficiently severe to meet criteria for referral to an inpatient psychiatric facility or a crisis stabilization unit
- Any prior history of an opioid overdose
- Medically cleared; Individuals with any of the following will be excluded:
- Any psychotic disorder or active homicidally
- Inability to perform consent due to impaired mental status
- Current substance intoxication or current (or within the past 1-month) mania, hypomania, mixed-episode, or psychosis
- Systolic blood pressure persistently elevated above 160mmHg, diastolic blood pressure greater than 100 mmHg, or heart rate >100bmp, in the ED
- Clinical Opioid Withdrawal Scale (COWS) score of 12 or greater
- History of hypersensitivity to ketamine, or experience of emergence reaction
- History of hypersensitivity to ondansetron or concurrently using apomorphine
- History of any illicit or recreational use of ketamine in the past 12 months
- Receipt of ketamine treatment for depression in the past 3 months
- History of DSM5 hallucinogen use disorder, intracranial mass or bleed, porphyria, thyrotoxicosis, seizure disorder other than from alcohol withdrawal, liver cirrhosis, or sleep apnea
- Cardiac or EKG abnormalities based on history, physical examination or the baseline EKG
- History within 6 months of thoracic surgery, lung cancer, head trauma, stroke, or myocardial infarction
- Liver dysfunction with LFTs >3x upper normal limit
- Current use of medications with known drug-drug interactions with ketamine (i.e., St. John's Wort, theophylline, opioid analgesics other than buprenorphine and methadone for the treatment OUD, Central Nervous System (CNS) depressants other than benzodiazepines or phenobarbital)
- Pregnant
- Patients who are breastfeeding
- ASA class 3 or greater or documented history of difficult airway in HER
- Active exacerbation of COPD or asthma
- Currently participating or anticipated to participate in a concurrent investigational clinical trial
- High risk for adverse emotional or behavioral reaction based on the opinion of the study investigators, including evidence of a personality disorder
Where in United States
- Brigham and Women's HospitalBoston, United States
About the trial
What the trial wants to find out
This is a pilot, double-blind, placebo-controlled randomized clinical trial of individuals with opioid use disorder (OUD) with suicidal ideation in the emergency department (ED) to receive either a single infusion of ketamine 0.8mg/kg (n=25) or saline placebo (n=25). The primary aim is to evaluate the safety of the ketamine treatment. The secondary aim is to determine the preliminary efficacy of opioid- and suicide-related outcomes.
The 2 groups in the trial
- KetamineTreatment being tested
This arm will receive ketamine (n=25)
- Saline PlaceboPlacebo, for comparison
This arm will receive the saline placebo (n=25)
Treatment: Saline Solution
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Ketamine for the Treatment for Opioid Use Disorder and Suicidal Ideation in the Emergency Department
- Record updated
- 8 April 2025